|
|
Volumn 12, Issue 9, 2011, Pages 825-
|
|
Off-label prescriptions: Patient safety first
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DUTASTERIDE;
FINASTERIDE;
PROSTATE SPECIFIC ANTIGEN;
STEROID 5ALPHA REDUCTASE INHIBITOR;
CANCER INCIDENCE;
CANCER PREVENTION;
CANCER RISK;
CANCER SCREENING;
CLINICAL DECISION MAKING;
DRUG INDUSTRY;
DRUG SAFETY;
EDITORIAL;
HEALTH CARE COST;
HUMAN;
MALIGNANT NEOPLASTIC DISEASE;
MEDICAL SOCIETY;
OFF LABEL DRUG USE;
PATIENT SAFETY;
PRACTICE GUIDELINE;
PRESCRIPTION;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROSTATE HYPERTROPHY;
DRUG COSTS;
DRUG INDUSTRY;
DRUG THERAPY;
EVIDENCE-BASED MEDICINE;
HUMANS;
MARKETING OF HEALTH SERVICES;
OFF-LABEL USE;
PATIENT RIGHTS;
RISK ASSESSMENT;
RISK FACTORS;
|
|
EID: 80052359745
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(11)70246-7 Document Type: Editorial |
|
Times cited : (5)
|
|
References (0)
|